News
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
Russia becomes the first country to deploy a cancer vaccine, launching trials within months. Using cutting-edge mRNA technology, the treatment is personalised to target a patient’s tumour. With ...
BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...
UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent. Already registered? If you don't have a login or your ...
HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...
2d
The Manila Times on MSNPfizer, BioNTech lose UK court appeal over Covid jabUS pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million-pound battle against US rival Moderna over the Covid-19 vaccine. The Appeals ...
Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Discover key takeaways from Moderna's Q2 2025 earnings call, including FDA approvals, cost reductions, pipeline strategies, and financial updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results